ClinicalTrials.gov
public full text
Public Domain
Three Months of Weekly Rifapentine and Isoniazid for M. Tuberculosis Infection
Open-label, multi-center, Phase III clinical trial to compare the effectiveness and tolerability of a three-month (12-dose) regimen of weekly rifapentine and isoniazid (3RPT/INH) to the effectiveness of a nine-month (270-dose)regimen of daily isoniazid (9INH) to prevent tuberculosis (TB) among high-risk tuberculin skin-test reactors, including children and HIV-infected persons, who require treatment of latent TB infection (LTBI).
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- TBTC Study 31: Rifapentine-containing Tuberculosis Treatment Shortening Regimens#136402
- TBTC Study 31: Rifapentine-containing Tuberculosis Treatment Shortening Regimens (S31/A5349)#1160027
- Tuberculosis Preventive Therapy Among Latent Tuberculosis Infection in HIV-infected Individuals#1371853
- Predictors of tuberculosis mortality among patients on treatment: A retrospective cohort study at a rural general hospital in Zambia#309460
- TBTC Study 29: Rifapentine During Intensive Phase Tuberculosis (TB) Treatment#839164
Record · ID 1395685
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive